CA2798701A1 - Alcohol-resistant extended release dosage forms comprising venlafaxine - Google Patents
Alcohol-resistant extended release dosage forms comprising venlafaxine Download PDFInfo
- Publication number
- CA2798701A1 CA2798701A1 CA2798701A CA2798701A CA2798701A1 CA 2798701 A1 CA2798701 A1 CA 2798701A1 CA 2798701 A CA2798701 A CA 2798701A CA 2798701 A CA2798701 A CA 2798701A CA 2798701 A1 CA2798701 A1 CA 2798701A1
- Authority
- CA
- Canada
- Prior art keywords
- percent
- weight
- granule
- amount
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002552 dosage form Substances 0.000 title claims abstract 44
- 229960004688 venlafaxine Drugs 0.000 title claims abstract 17
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 title claims abstract 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract 14
- 238000013265 extended release Methods 0.000 title claims abstract 9
- 239000007931 coated granule Substances 0.000 claims abstract 39
- 239000011159 matrix material Substances 0.000 claims abstract 25
- 239000004034 viscosity adjusting agent Substances 0.000 claims abstract 21
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000012453 solvate Substances 0.000 claims abstract 12
- 239000006186 oral dosage form Substances 0.000 claims abstract 11
- 150000002632 lipids Chemical class 0.000 claims abstract 8
- 239000008187 granular material Substances 0.000 claims 39
- 239000011248 coating agent Substances 0.000 claims 22
- 238000000576 coating method Methods 0.000 claims 22
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 10
- 239000001993 wax Substances 0.000 claims 8
- 230000000181 anti-adherent effect Effects 0.000 claims 7
- 239000003911 antiadherent Substances 0.000 claims 7
- 239000001856 Ethyl cellulose Substances 0.000 claims 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims 6
- 229920001249 ethyl cellulose Polymers 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 4
- -1 gums Polymers 0.000 claims 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 4
- 229920000609 methyl cellulose Polymers 0.000 claims 4
- 239000001923 methylcellulose Substances 0.000 claims 4
- 235000010981 methylcellulose Nutrition 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 229920001577 copolymer Polymers 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims 2
- 244000247812 Amorphophallus rivieri Species 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 229920002752 Konjac Polymers 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 229920001800 Shellac Polymers 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 235000010418 carrageenan Nutrition 0.000 claims 2
- 239000000679 carrageenan Substances 0.000 claims 2
- 229920001525 carrageenan Polymers 0.000 claims 2
- 229940113118 carrageenan Drugs 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 235000013312 flour Nutrition 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 235000010485 konjac Nutrition 0.000 claims 2
- 239000000252 konjac Substances 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 239000001814 pectin Substances 0.000 claims 2
- 235000010987 pectin Nutrition 0.000 claims 2
- 229920001277 pectin Polymers 0.000 claims 2
- 239000004584 polyacrylic acid Substances 0.000 claims 2
- 239000004208 shellac Substances 0.000 claims 2
- 229940113147 shellac Drugs 0.000 claims 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 2
- 235000013874 shellac Nutrition 0.000 claims 2
- 235000010413 sodium alginate Nutrition 0.000 claims 2
- 239000000661 sodium alginate Substances 0.000 claims 2
- 229940005550 sodium alginate Drugs 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000000230 xanthan gum Substances 0.000 claims 2
- 235000010493 xanthan gum Nutrition 0.000 claims 2
- 229920001285 xanthan gum Polymers 0.000 claims 2
- 229940082509 xanthan gum Drugs 0.000 claims 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 229920006397 acrylic thermoplastic Polymers 0.000 claims 1
- 229940075534 amino methacrylate copolymer Drugs 0.000 claims 1
- 235000013871 bee wax Nutrition 0.000 claims 1
- 229940092738 beeswax Drugs 0.000 claims 1
- 239000012166 beeswax Substances 0.000 claims 1
- 239000004203 carnauba wax Substances 0.000 claims 1
- 229940082483 carnauba wax Drugs 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002416 venlafaxine hydrochloride Drugs 0.000 claims 1
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002348 vinylic group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33352710P | 2010-05-11 | 2010-05-11 | |
| US61/333,527 | 2010-05-11 | ||
| PCT/US2011/035768 WO2011143119A1 (en) | 2010-05-11 | 2011-05-09 | Alcohol-resistant extended release dosage forms comprising venlafaxine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2798701A1 true CA2798701A1 (en) | 2011-11-17 |
Family
ID=44461928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2798701A Abandoned CA2798701A1 (en) | 2010-05-11 | 2011-05-09 | Alcohol-resistant extended release dosage forms comprising venlafaxine |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130171256A1 (enExample) |
| EP (1) | EP2579857A1 (enExample) |
| JP (1) | JP2013526522A (enExample) |
| CA (1) | CA2798701A1 (enExample) |
| MX (1) | MX2012013023A (enExample) |
| WO (1) | WO2011143119A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3164117T3 (da) | 2014-07-03 | 2023-12-04 | SpecGx LLC | Misbrugssikre formuleringer med øjeblikkelig frigivelse omfattende ikke-cellulose-polysaccharider |
| US20180344649A1 (en) | 2015-09-29 | 2018-12-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
| US11478426B2 (en) | 2018-09-25 | 2022-10-25 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US5223264A (en) | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| IL149055A0 (en) * | 2002-04-09 | 2002-11-10 | Karma Pharm Ltd | Extended release composition comprising as active compound venlafaxine hydrochloride |
| IN2003MU00504A (enExample) * | 2003-06-05 | 2005-05-13 | Alembic Ltd | |
| HUP0303382A2 (hu) * | 2003-10-10 | 2005-08-29 | EGIS Gyógyszergyár Rt. | Venlafaxin-hidroklorid-tartalmú pelletek |
| WO2007112574A1 (en) * | 2006-04-03 | 2007-10-11 | Isa Odidi | Extended release composition of venlafaxine |
| US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| DK2200593T5 (en) * | 2007-09-13 | 2016-12-12 | Cima Labs Inc | Hog-resistant pharmaceutical formulation |
-
2011
- 2011-05-09 EP EP11719443.1A patent/EP2579857A1/en not_active Withdrawn
- 2011-05-09 WO PCT/US2011/035768 patent/WO2011143119A1/en not_active Ceased
- 2011-05-09 MX MX2012013023A patent/MX2012013023A/es unknown
- 2011-05-09 US US13/715,698 patent/US20130171256A1/en not_active Abandoned
- 2011-05-09 JP JP2013510208A patent/JP2013526522A/ja active Pending
- 2011-05-09 CA CA2798701A patent/CA2798701A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011143119A1 (en) | 2011-11-17 |
| MX2012013023A (es) | 2012-12-17 |
| US20130171256A1 (en) | 2013-07-04 |
| JP2013526522A (ja) | 2013-06-24 |
| EP2579857A1 (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2798700A1 (en) | Alcohol-resistant formulations | |
| JP5661062B2 (ja) | ヒドロコドン放出制御製剤 | |
| AU2010339882B2 (en) | Abuse-resistant formulations | |
| JP4971159B2 (ja) | プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用 | |
| CA2704646C (en) | Sustained-release tablets with hydromorphone | |
| JP2022504242A (ja) | 耐アルコール性製剤 | |
| CN104902880B (zh) | 包含氢吗啡酮和纳洛酮的药物组合物 | |
| NO20130366A1 (no) | Bruk av bindemidler for fremstilling av lagringsstabile formuleringer | |
| CN104136004B (zh) | 多西拉敏和吡哆醇和/或其代谢物或盐的制剂 | |
| CN103002882B (zh) | 不含活性剂之颗粒及包含其之片剂的制备 | |
| WO2011049309A2 (ko) | 속효성과 지속성을 동시에 갖는 약제학적 조성물 | |
| US9717700B2 (en) | Methods for overcoming resistance to tramadol | |
| JP2013526521A5 (enExample) | ||
| WO2006118265A1 (ja) | 抗痴呆薬を含有する組成物 | |
| NO20121414A1 (no) | Farmasoytiske sammensetninger omfattende hydromorfon og nalokson | |
| CA2798702A1 (en) | Alcoholresistant metoprolol-containing extended-release oral dosage forms | |
| CA2415154C (en) | Modified release formulations of selective serotonin re-uptake inhibitors | |
| CA2798701A1 (en) | Alcohol-resistant extended release dosage forms comprising venlafaxine | |
| WO2012052834A2 (en) | Multiple unit particulate system comprising metoprolol succinate | |
| WO2009065130A2 (en) | Modified release formulations of diltiazem | |
| WO2009024858A1 (en) | Controlled release dosage form of galantamine | |
| JP2013526522A5 (enExample) | ||
| RU2584653C2 (ru) | Фармацевтическая композиция с пролонгированным высвобождением с антипсихотической активностью и способы её получения | |
| WO2012131722A1 (en) | Controlled release composition of betahistine | |
| WO2022132978A1 (en) | Modified release solid oral dosage form for once daily administration of monomethyl fumarate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20170510 |